GLOBAL PRIOR AUTHORIZATION AUTOMATION MARKET (2026 - 2030)

The Global Prior Authorization Automation Market was valued at USD 1.38 Billion in 2025 and is projected to reach a market size of USD 4.12 Billion by the end of 2030. Over the forecast period of 2026–2030, the market is projected to grow at a CAGR of 24.5%.

Most healthcare providers do not discover how much revenue is lost to prior authorization delays until auditors benchmark their denial rates. By then, the administrative burden has compounded: physicians spend hours each week submitting, appealing, and resubmitting authorisation requests to payers whose requirements differ by plan, procedure code, and geography — while patients wait days or weeks for care decisions that clinical evidence supports immediately. That systemic friction — endemic across the US healthcare system and increasingly apparent in other developed markets — has become operationally, clinically, and financially untenable in a world where physician burnout is at historic highs, payer audit intensity is increasing, and the volume of procedures requiring prior authorisation has grown by an estimated 20–25% since 2020. Delayed authorisations contribute to patient harm through postponed care, generate billions in administrative waste, and represent a documented and systematically underaddressed structural failure in healthcare payment systems.

The Global Prior Authorization Automation Market encompasses the full commercial ecosystem of software platforms, artificial intelligence and machine learning engines, workflow orchestration tools, payer connectivity networks, and analytics capabilities that enable healthcare providers, payers, and pharmacy benefit managers to automate, accelerate, and optimise the prior authorisation process across medical, surgical, diagnostic, and pharmaceutical benefit categories. At its core are the AI-driven determination platforms that analyse patient clinical data against payer criteria, generate real-time authorisation predictions, submit electronic prior authorisation (ePA) requests through payer-connected APIs, and manage the end-to-end workflow from initial submission through approval, denial, appeal, and resubmission — replacing manual phone and fax processes that currently consume an estimated 16 hours of administrative time per physician per week in the United States alone.

Key Market Insights:

• AI-driven prior authorization can automate 50–75% of manual tasks, significantly improving efficiency and reducing administrative burden.
• Automation in prior authorization and related workflows can contribute to 13–25% administrative cost savings for healthcare payers.
• CMS finalized its Prior Authorization Rule in January 2024, requiring Medicare Advantage, Medicaid, and CHIP payers to implement Fast Healthcare Interoperability Resources (FHIR) APIs for electronic prior authorisation by 2027, creating a regulatory mandate that is accelerating technology investment across both provider and payer segments.
• The share of specialty pharmaceutical claims requiring prior authorisation has grown from approximately 38% in 2020 to over 56% in 2025, driven by the expansion of high-cost biologic and gene therapy pipelines, creating the highest-growth application segment in the prior authorisation automation market.
• In September 2025, Availity partnered with Rhyme Health to integrate real-time clinical data exchange into its prior authorisation workflow, enabling automated clinical documentation submission alongside the ePA request and materially reducing the documentation burden that generates the majority of peer-to-peer review delays.
• In June 2025, Cohere Health raised USD 90 million in Series C funding to expand its AI-powered clinical intelligence platform for prior authorisation, reflecting strong investor conviction in the market's growth trajectory and the commercial viability of AI-driven clinical appropriateness determination.

Research Methodology:

1. Scope & Definitions

• Market boundary: commercial revenues from prior authorisation automation software platforms, AI/ML determination engines, electronic prior authorisation (ePA) submission tools, payer connectivity networks, clinical decision support tools embedded in the PA workflow, and analytics and reporting solutions that measure authorisation performance across provider and payer organisations.
• Excluded: general electronic health record (EHR) systems and practice management software without dedicated prior authorisation automation modules; revenue cycle management platforms whose prior authorisation capability is incidental rather than purpose-built; and claims adjudication and payment processing systems downstream of the authorisation determination.
• Application categories covered: medical imaging and diagnostics authorisation, specialty pharmaceutical and biologic PA, surgical and procedural approvals, durable medical equipment authorisation, and behavioural health and mental health service PA.
• Geography: global, with regional breakdowns for North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Timeframe: base year 2025; forecast period 2026–2030.
• Segmentation rules are MECE; double counting is prevented by applying a single transaction-layer boundary (platform licence or managed service contract — not resale or sub-licence).

2. Evidence Collection (Primary + Secondary)

• Primary: structured interviews across the value chain — physician practice administrators, hospital revenue cycle directors, health plan medical management leaders, pharmacy benefit management operations heads, health IT procurement officers, and prior authorisation automation platform executives.
• Secondary: verifiable data from organisations relevant to this market including the American Medical Association PA reform surveys, CAQH Index annual reports, CMS rulemaking documentation, AHIP cost-of-care administrative studies, HL7 FHIR PA implementation guides, and peer-reviewed health services research on authorisation delay patient outcomes. All key claims are sourced with evidence inside the report.

3. Triangulation & Validation

• Two sizing approaches applied per segment: bottom-up (active platform deployments by provider organisation type and payer × average annual revenue per deployment, validated against vendor financial disclosures and funding round valuations) and top-down (total prior authorisation administrative spend filtered to technology and automation sub-categories, reconciled to published market data from CAQH and AHIP sources).
• Conflicting source resolution: where primary and secondary data diverge by more than 10%, a third data point is sought and the variance documented. Vendor automation rate claims are validated against independently documented customer deployment outcomes where available.

4. Presentation & Auditability

• All findings are presented with source-linked evidence and traceable assumptions. Segmentation is MECE; each chapter sums to 100% using an Others bucket.
• Report includes a vendor benchmarking matrix across core platform capabilities (EHR integration depth, payer connectivity breadth, AI determination accuracy, ePA submission speed, clinical documentation automation, denial management workflow), a total cost of prior authorisation framework, and a maturity model mapping organisations from fully manual fax-based processes to fully autonomous real-time determination.
• Formatted for enterprise decision use with stakeholder-specific implication sections for hospital revenue cycle leaders, physician practice administrators, health plan medical management heads, pharmacy benefit managers, and health IT investors.

Market Drivers:

CMS Regulatory Mandate and FHIR Interoperability Requirements

The CMS Interoperability and Prior Authorization Rule (CMS-0057-F), finalised in January 2024, represents the most consequential regulatory catalyst in the prior authorisation automation market. The rule requires Medicare Advantage organisations, Medicaid managed care plans, CHIP, and Qualified Health Plans to implement FHIR R4-based APIs enabling electronic prior authorisation submission, real-time decision transparency, and publicly reportable PA metrics by January 2027. This creates a hard compliance deadline that is forcing payer technology infrastructure investment at scale — and simultaneously enabling provider automation platforms to access payer PA criteria and decision systems programmatically for the first time.

Physician Burnout and Administrative Burden Crisis

The American Medical Association's 2024 Prior Authorization Physician Survey documents that physicians complete an average of 45 PA requests per week, with 39% reporting that they have had a patient whose condition seriously deteriorated while waiting for an authorisation — and 25% reporting a PA-related adverse patient event. The administrative burden of prior authorisation is now clinically documented as a patient safety risk, not only a physician satisfaction issue. Health systems facing physician attrition in competitive recruiting markets are investing in prior authorisation automation as a direct workforce retention strategy, with documented reductions in administrative time of 60–80% generating measurable improvements in physician satisfaction scores and reducing the per-physician annual administrative cost burden by an estimated USD 80,000–120,000 when fully automated platforms replace manual processes.

Market Restraints and Challenges:

The primary adoption barrier is payer connectivity fragmentation: effective prior authorisation automation requires real-time electronic connections to each payer's PA submission and determination system — but the US payer landscape comprises thousands of health plans operating different portal architectures, eligibility APIs, and authorisation criteria management systems with varying degrees of electronic connectivity. Provider organisations with complex payer mixes face significant implementation complexity in achieving coverage across their full payer population, and the authorisation burden on non-automated payers tends to intensify as staff concentrate manual effort on remaining gaps. The CMS FHIR mandate will significantly reduce this fragmentation for Medicare Advantage and Medicaid after 2027, but commercial payer connectivity will remain a coverage variable that differentiates platform value for the foreseeable forecast period.

Market Opportunities:

The integration of prior authorisation automation with clinical decision support at the point of ordering represents the highest-value expansion opportunity: platforms that can embed authorisation eligibility and likely approval probability checks at the moment a physician selects a procedure code, orders a medication, or refers a patient — before the PA request is initiated — can eliminate a significant proportion of submissions that will be denied, redirecting clinical decisions toward covered alternatives in real time. This point-of-care PA intelligence capability, now being commercialised by platforms including Cohere Health and Olive AI, represents a premium tier of the market that commands higher per-transaction revenue than submission automation alone. Additionally, the international expansion opportunity is significant: the UK's NHS pre-authorisation reform programme, Australian private health insurer PA requirements, and Asia-Pacific payer digitisation initiatives represent material addressable markets for the core automation capabilities developed in the US context.

How This Market Works End-to-End:

Prior authorisation automation operates as a real-time intelligence and workflow system embedded across the clinical and administrative care delivery process. Understanding the market requires tracing the value flow across seven interconnected stages:

1. Benefits Investigation and PA Requirement Identification: The automation workflow begins at the point of clinical decision — when a physician selects a procedure, orders a medication, or generates a referral. Integrated platforms query real-time benefits eligibility APIs to determine whether the specific service, drug, or procedure requires prior authorisation for the patient's active plan — and if so, what clinical documentation and criteria the payer requires. This front-end identification step prevents downstream denials by ensuring that authorisation is initiated before scheduling, dispensing, or service delivery occurs.

2. Clinical Documentation Collection and Packaging: Once PA requirement is confirmed, platforms automate the collection of supporting clinical documentation — pulling relevant diagnosis codes, clinical notes, lab results, imaging reports, and prior treatment history directly from the EHR or pharmacy management system. AI-powered natural language processing extracts the specific clinical evidence elements required by each payer's PA criteria, assembling a structured clinical package that addresses the payer's determination criteria without requiring manual physician documentation of each element. This stage represents the highest manual burden in the existing process and the greatest per-transaction time saving from automation.

3. Payer Criteria Matching and Determination Prediction: Platform AI engines match the assembled clinical documentation against the specific payer's coverage criteria, clinical guidelines, and formulary requirements for the requested service. Advanced platforms maintain continuously updated payer criteria libraries — incorporating CMS Local Coverage Determinations, payer Clinical Coverage Policies, and formulary tier requirements — and generate an approval probability score that enables clinical teams to assess authorisation risk before submission. Cases with high approval probability are routed for automated submission; cases with low approval probability are flagged for clinical review or alternative pathway identification.

4. Electronic PA Submission via Payer Connectivity: Platforms submit the clinical documentation package electronically to the payer through API connections (FHIR-based for CMS-compliant payers), EDI 278 transactions, payer portal integrations, or proprietary health information network connections. Electronic submission replaces the phone and fax processes that currently account for an estimated 30–40% of all PA transactions, with submission processing times reducing from hours to seconds for electronically connected payers. Platforms track submission status in real time and manage follow-up enquiries within the authorisation workflow.

5. Real-Time or Near-Real-Time Determination Receipt: For payers with FHIR API connectivity and AI-powered determination engines — a rapidly expanding category driven by the CMS mandate — platforms receive determination decisions in minutes or hours rather than days. Auto-approved determinations are returned to the clinical workflow immediately; pending determinations requiring clinical review are queued with status tracking and escalation management. Platforms maintain audit trails of all determination communications for compliance and appeal documentation purposes.

6. Denial Management and Appeal Automation: When authorisation is denied, platforms automate the appeal workflow — identifying the specific denial reason code, matching it to the clinical evidence required for a successful appeal, assembling the appeal documentation package, and submitting the first-level appeal electronically within the payer's required appeal window. AI-driven appeal optimisation analyses historical denial and overturn patterns by payer, procedure, and denial reason to prioritise appeal investment on cases with the highest overturn probability and financial value.

7. Performance Analytics and Programme Optimisation: Mature prior authorisation automation programmes measure performance at the transaction level — tracking approval rates, determination turnaround time, denial rates by payer and procedure, appeal overturn rates, and net revenue protected per authorisation submitted. Analytics platforms identify payer-specific criteria changes that are driving increased denials, procedure categories with systematically low approval rates that may indicate coverage policy changes requiring clinical documentation protocol updates, and physician ordering patterns that generate disproportionate PA administrative burden.

Why This Market Matters Now:

The CMS Prior Authorization Rule has created a defined regulatory timeline that is converting prior authorisation automation from a competitive advantage for early adopters into a compliance baseline for all payers by 2027. For providers, the FHIR mandate means that the payer connectivity barriers that made full automation impractical will be progressively removed across Medicare Advantage and Medicaid — the largest payer segments by covered lives. For payers, the mandate requires technology infrastructure investment that creates the API surface area provider automation platforms need to deliver real-time determination. The regulatory catalyst is accelerating a market transition that market forces were already driving: the administrative cost of manual prior authorisation has grown beyond the point where it can be managed through staffing alone, and the clinical consequences of authorisation delay are increasingly visible in quality measurement and patient safety reporting.

The AI determination accuracy milestone is equally significant. The prior authorisation system has historically required physician-level clinical judgement for each determination — a constraint that made full automation technically implausible. Platform AI engines trained on millions of determination outcomes have now crossed the accuracy threshold — 90–95% agreement with expert clinical review on clearly appropriate cases — that enables real-time autonomous approval for the majority of routine PA requests. This technical milestone changes the market's growth ceiling: automation is no longer limited to administrative workflow optimisation but extends to the determination itself, enabling full process transformation rather than incremental efficiency improvement.

What Matters Most When Evaluating Claims in This Market:

Vendors in the prior authorisation automation market make a range of platform capability claims that require structured evaluation criteria. The framework below supports rigorous assessment:

The Decision Lens:

A structured framework for hospital revenue cycle leaders, physician practice administrators, and health plan medical management heads evaluating prior authorisation automation investments:

1. Map your current PA volume, payer mix, and denial rate baseline first: Effective prior authorisation automation investments are sized against quantified current-state cost and revenue impact. Begin by measuring your current PA transaction volume by payer, procedure category, and clinical service line; your current denial rate by payer and procedure; and your average cost per PA transaction including physician time, administrative staff time, and appeal processing. This baseline establishes the ROI denominator and identifies the specific payer-procedure combinations where automation investment will generate the highest return.

2. Evaluate EHR integration depth before payer connectivity breadth: Prior authorisation automation delivers its highest value when embedded in the physician ordering workflow — at the moment the PA-required order is placed, not in a separate administrative portal after the clinical decision is made. Assess whether prospective platforms integrate at the order-entry level within your existing EHR (Epic, Oracle Health, Cerner) or require a separate workflow step that maintains physician exposure to the PA process. Deep EHR integration is the primary predictor of physician adoption and the primary source of the time-saving value propositions that justify automation investment.

3. Assess payer connectivity coverage for your specific top-10 payers: Aggregate payer connectivity claims are less informative than coverage of the specific payers that generate the majority of your PA volume and denial rate. Request documentation of electronic submission capability — FHIR API, EDI 278, or portal integration — for each of your top 10 payers by PA transaction volume, and evaluate the quality of real-time determination connectivity versus status-tracking-only connectivity for each payer type.

4. Evaluate AI determination model transparency and clinical accuracy: Request access to the platform's determination accuracy methodology — specifically the proportion of submitted cases that receive autonomous determination versus human clinical review routing, the agreement rate between AI determination and physician review on the full case population (not only the auto-approved subset), and the payer-specific validation datasets used to calibrate determination accuracy. AI accuracy claims that are not validated on payer-specific criteria are not reliable performance predictors.

5. Model the total cost of prior authorisation against the programme investment: Before building the business case for platform investment, quantify your current unmanaged PA administrative cost — the fully loaded cost per transaction including physician time at appropriate opportunity cost, administrative staff FTEs, denial write-off rate, and net revenue at risk from authorisation-related delays. This total-cost baseline typically generates a business case for automation investment that is significantly stronger than the direct administrative cost saving alone.

6. Plan for payer landscape changes through the CMS mandate implementation period: The FHIR connectivity landscape will change materially between 2025 and 2027 as CMS mandate implementation progresses. Ensure that contract terms with automation platform vendors include obligations to maintain FHIR compliance and expand payer connectivity as new API connections become available — and evaluate vendors' documented roadmap for CMS mandate alignment in their top-payer connectivity priority list.

7. Assess denial management and appeal capability alongside submission automation: The financial return from prior authorisation automation is not limited to administrative cost reduction — it includes denial rate reduction and appeal overturn rate improvement that directly protect net patient service revenue. Evaluate whether platforms offer integrated denial management and appeal automation that applies AI-driven appeal optimisation to the cases that generate the highest overturnable denial value.

The Contrarian View:

• Treating prior authorisation automation as a revenue cycle problem when it is primarily a clinical workflow integration problem: The most common implementation failure in this market is deploying PA automation as a standalone revenue cycle management tool operated by billing staff, rather than integrating it into the physician ordering workflow where the highest-value automation occurs. Platforms that are not embedded in the point-of-care ordering decision cannot prevent inappropriate submissions, cannot deliver real-time formulary and coverage guidance to prescribers, and cannot capture the physician time savings that represent the largest component of the total value proposition.
• Over-indexing on approval rate metrics while under-measuring determination turnaround time: The clinical quality impact of prior authorisation automation is primarily driven by elapsed time from ordering to approval — not by approval rate improvement, which is typically modest. Organisations that measure automation success exclusively through denial rate reduction miss the patient care quality improvement from authorisation delay elimination that represents the highest-value outcome of programme investment.

Practical Implications by Stakeholder:

Hospital Revenue Cycle Leaders:

• Prioritise EHR-integrated, payer-connected platform architectures over standalone PA portals: automation value is destroyed when physicians must access a separate system to manage authorisation workflows, and denial prevention depends on point-of-care integration that standalone tools cannot deliver.
• Establish PA performance metrics at the payer and procedure level — not only aggregate — to identify the specific payer-procedure combinations generating disproportionate denial burden and target automation investment accordingly.
• Build the PA automation business case with net revenue protection framing, not only administrative cost reduction: the annual revenue at risk from PA-related denials and write-offs typically exceeds administrative cost savings by a factor of 3–5 at well-run health systems, and presenting the full financial case to CFO leadership generates larger and faster investment approval.

Physician Practice Administrators:

• Evaluate PA automation platforms based on physician time reduction as the primary metric — not administrative staff time — since physician time carries a higher opportunity cost and physician satisfaction with PA burden is a direct driver of practice retention and recruitment outcomes that have material financial value.
• Prioritise platforms with documented specialty-specific clinical criteria libraries for your practice's top PA-required service categories: general-purpose PA platforms that require manual criteria configuration for specialty procedures generate significantly lower automation rates than specialty-optimised determination engines with pre-built criteria matching for oncology, cardiology, orthopaedics, or neurology PA workflows.
• Build appeal automation into the programme from implementation: the highest-value prior authorisation automation investment for physician practices is frequently the denial appeal workflow, where AI-driven case prioritisation and documentation assembly can recover 20–35% of initially denied PA revenue that would otherwise be written off due to administrative resource constraints on appeal processing.

Healh Plan Medical Management Leaders:

• Invest in FHIR API infrastructure ahead of the CMS 2027 mandate rather than at the compliance deadline: organisations that implement FHIR PA connectivity early benefit from operational learning, provider relationship improvements, and administrative cost reductions on payer-side determination processing that late implementers will not access.
• Evaluate AI-driven clinical appropriateness determination platforms for prospective criteria application: payers that deploy AI determination engines to manage high-volume routine PA categories can reduce medical management FTE requirements while improving determination consistency, reducing provider appeals, and delivering measurably faster decisions that improve member and provider satisfaction scores.
• Engage provider-facing automation platforms as connectivity partners rather than treating them as adversarial: payers with published FHIR APIs and documented integration programmes for provider automation platforms generate lower administrative friction, higher-quality clinical documentation submissions, and lower appeal rates than payers that maintain opaque portal-only submission requirements.

Pharmacy Benefit Managers:

• Pharmacy prior authorisation automation is the highest-volume and fastest-growing sub-category of this market: PBMs managing specialty pharmaceutical formularies face PA volumes that are growing at 15–20% annually as high-cost biologic and gene therapy pipelines expand, and manual PA processing creates member access delays that generate regulatory and accreditation scrutiny.
• Real-time pharmacy benefit investigation tools that flag PA requirements at the point of prescribing — before the prescription is transmitted to the pharmacy — represent the highest-value PA automation investment for PBMs, as they redirect prescriber decisions toward covered alternatives before patient-visible access failures occur.
• Step-therapy compliance automation is a material cost control opportunity within the pharmacy PA category: platforms that document, verify, and automatically demonstrate step-therapy compliance in the PA submission reduce physician documentation burden, reduce prior authorisation review time, and prevent coverage disputes that generate administrative cost and member dissatisfaction disproportionate to their clinical significance.

Health IT Investors and Private Equity:

• Prior authorisation automation is one of the highest-conviction segments in healthcare IT investment in 2025–2030: the regulatory catalyst of the CMS FHIR mandate, the documented administrative cost burden of USD 40 billion annually, and the AI accuracy inflection point create a simultaneous demand shock and technical enablement that characterises best-in-class healthcare IT investment theses.
• Platform consolidation dynamics are creating a bifurcated competitive landscape: EHR-native PA automation from Epic, Oracle Health, and Veradigm is expanding as a default option for organisations within those ecosystems, while standalone platforms must demonstrate superior payer connectivity breadth, AI determination accuracy, or specialty-specific clinical criteria depth to justify independent deployment cost — watch for accelerated M&A as standalone vendors seek scale.
• International expansion is an undervalued growth pathway for US prior authorisation automation platforms: the core capabilities — FHIR-based payer API connectivity, AI clinical criteria matching, and denial management automation — are directly applicable to UK private health insurer pre-authorisation, Australian private health fund PA requirements, and Middle East insurance-funded healthcare PA workflows that are at an earlier stage of digitisation but structurally similar to the US market circa 2018–2020.

GLOBAL PRIOR AUTHORIZATION AUTOMATION MARKET

Market Segmentation:

Global Prior Authorization Automation Market — By Component

• Introduction/Key Findings
• AI & Machine Learning Platforms
• Rules Engine Software
• Workflow Automation Tools
• Analytics & Reporting Solutions
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

AI & Machine Learning Platforms is the dominant component in 2025, as organisations prioritise AI-driven clinical determination capability — approval probability scoring, autonomous case processing, and denial prediction — as the foundation of their prior authorisation automation programme before expanding into broader workflow and analytics layers.

Analytics & Reporting Solutions is the fastest-growing component, driven by payer regulatory reporting requirements under the CMS mandate and the increasing demand from health system revenue cycle leadership for transaction-level performance visibility that enables continuous denial rate and turnaround time optimisation.

Global Prior Authorization Automation Market — By Deployment Mode

• Introduction/Key Findings
• Cloud-Based Deployment
• On-Premises Deployment
• Hybrid Deployment
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Cloud-Based Deployment is dominant in 2025, offering continuous payer criteria database updates without client-side data management, multi-site provider visibility from a single platform instance, and lower implementation barriers — advantages particularly valued by physician group practices and regional health systems without dedicated health IT infrastructure teams.

Hybrid Deployment is the fastest-growing mode, adopted by large health systems and academic medical centres that require cloud-based payer connectivity and AI determination capability but maintain on-premises EHR environments and clinical data governance requirements that prevent full cloud migration of patient clinical documentation.

Global Prior Authorization Automation Market — By End User

• Introduction/Key Findings
• Hospitals & Health Systems
• Physician Practices & Ambulatory Clinics
• Health Insurance Payers
• Pharmacy Benefit Managers
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Prior Authorization Automation Market — By Application

• Introduction/Key Findings
• Medical Imaging & Diagnostics
• Specialty Pharmaceuticals & Biologics
• Surgical & Procedural Approvals
• Durable Medical Equipment
• Behavioural Health & Mental Health Services
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Prior Authorization Automation Market — By Organisation Size

• Introduction/Key Findings
• Large Health Systems
• Small & Mid-Size Provider Organisations
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Prior Authorization Automation Market — By Geography

• Introduction/Key Findings
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
• Y-O-Y Growth Trend & Opportunity Analysis

North America dominates in 2025, driven by the US healthcare system's prior authorisation volume — the largest and most complex payer PA environment globally — combined with the CMS regulatory mandate, active health IT investment ecosystem, and the concentration of major prior authorisation automation platform vendors and their primary customer base in the US market.

Asia-Pacific is the fastest-growing region, driven by rapid expansion of private health insurance coverage in India, China, and Southeast Asia, increasing payer digitisation and pre-authorisation programme implementation, and the adoption of cloud-based healthcare administrative platforms by regional hospital groups and insurance payers seeking to manage growing PA volumes without proportional administrative staff expansion.

Latest Market News (2025–2026):

• March 2025 — Cohere Health Expands AI Determination Platform to Behavioural Health: Cohere Health extended its AI-powered clinical intelligence platform to cover behavioural health and mental health prior authorisation, addressing one of the highest-growth and most clinically sensitive PA categories — where authorisation delays carry documented risk of patient harm and regulatory scrutiny under federal mental health parity requirements.
• January 2025 — Epic Launches Enhanced Real-Time Benefits and PA Integration: Epic Systems released enhanced real-time benefits investigation and prior authorisation workflow tools within the Epic MyChart and Epic Orders environments, deepening its native PA automation capability and increasing pressure on standalone PA automation vendors to demonstrate superior payer connectivity and AI determination accuracy for Epic-installed providers.
• February 2025 — Availity Expands Payer Connectivity Network to 2,200 Payers: Availity announced expansion of its payer connectivity network to over 2,200 health plan connections, including FHIR-based electronic prior authorisation APIs for the top 100 US health plans by covered lives — representing a significant advance in the payer connectivity coverage that provider automation platforms require to deliver full-population PA automation.
• November 2025 — CMS Publishes FHIR PA API Implementation Guidance: CMS released detailed technical implementation guidance for the FHIR Prior Authorization API requirement effective January 2027, providing payer technology teams with the specific implementation specifications required to comply with the mandate and enabling provider automation platform vendors to accelerate FHIR connectivity development against a confirmed technical standard.

Key Players in the Market:

• Cohere Health
• Availity LLC
• Olive AI
• Rhyme Health (formerly PriorAuthNow)
• Infinitus Systems
• Myndshft Technologies
• Waystar Health
• Change Healthcare (UnitedHealth Group)
• Surescripts
• CoverMyMeds (McKesson)